Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 3242301, 9 pages
https://doi.org/10.1155/2017/3242301
Review Article

Clinical Efficacy and Safety of Total Glucosides of Paeony for Primary Sjögren’s Syndrome: A Systematic Review

1Department of Rheumatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China
2Graduate School, Hunan University of Traditional Chinese Medicine, Changsha 410007, China
3Chongqing Engineering Technology Research Center of Traditional Chinese Medicine Characteristics on Diagnosis and Treatment, Chongqing 400021, China

Correspondence should be addressed to Yanping Li; moc.361@gnipnayilsqc and Bin Wu; moc.621@nnibuuw

Received 7 December 2016; Revised 3 April 2017; Accepted 9 May 2017; Published 31 May 2017

Academic Editor: Simon Stebbings

Copyright © 2017 Liang Jin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Maślińska, M. Przygodzka, B. Kwiatkowska, and K. Sikorska-Siudek, “Sjögren’s syndrome: still not fully understood disease,” Rheumatology International, vol. 35, no. 2, pp. 233–241, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Brito-Zerón, M. Ramos-Casals, and E-Stf Group, “Advances in the understanding and treatment of systemic complications in Sjögrenʼs syndrome,” Current Opinion in Rheumatology, vol. 26, no. 5, pp. 520–527, 2014. View at Publisher · View at Google Scholar
  3. S.-Y. Zhang, “The TCM etiology, pathogenesy and differential treatment for Sjogren's syndrome,” Journal of Traditional Chinese Medicine, vol. 31, no. 1, pp. 73–78, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Lendrem, S. Mitchell, P. McMeekin et al., “Health-related utility values of patients with primary Sjögren's syndrome and its predictors,” Annals of the Rheumatic Diseases, vol. 73, no. 7, pp. 1362–1368, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Barone and S. Colafrancesco, “Sjogren's syndrome: from pathogenesis to novel therapeutic targets,” Clinical and Experimental Rheumatology, vol. 34, no. 4, pp. 58–62, 2016. View at Google Scholar
  6. F. Ferro, R. Vagelli, C. Bruni et al., “One year in review 2016: Sjögren's syndrome,” Clinical and Experimental Rheumatology, vol. 34, no. 2, pp. 161–171, 2016. View at Google Scholar · View at Scopus
  7. M. Ramos-Casals, G. A. Tzioufas, H. J. Stone, A. Sisó, and X. Bosch, “Treatment of primary Sjögren syndrome: a systematic review,” Journal of the American Medical Association, vol. 304, no. 4, pp. 452–460, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. J. F. Van Nimwegen, R. V. Moerman, N. Sillevis Smitt, E. Brouwer, H. Bootsma, and A. Vissink, “Safety of treatments for primary Sjögrens syndrome,” Expert Opinion on Drug Safety, vol. 15, no. 4, pp. 513–524, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. X. Ma, Y.-H. Chi, M. Niu et al., “Metabolomics coupled with multivariate data and pathway analysis on potential biomarkers in cholestasis and intervention effect of Paeonia lactiflora pall.,” Frontiers in Pharmacology, vol. 7, article no. 14, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. C. L. Li, J. He, Z. G. Li, L. W. Zheng, and H. Hua, “Effects of total glucosides of paeony for delaying onset of Sjogren's syndrome: an animal study,” Journal of Cranio-Maxillofacial Surgery, vol. 41, no. 7, pp. 610–615, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Luo, D.-E. Jin, G.-Y. Yang et al., “Total glucosides of paeony for rheumatoid arthritis: A protocol for a systematic review,” BMJ Open, vol. 6, no. 3, Article ID e010116, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. H.-F. Zhang, W.-G. Xiao, and P. Hou, “Clinical study of total glucosides of paeony in patients with systemic lupus erythematosus,” Chinese Journal of Integrated Traditional and Western, vol. 31, no. 4, pp. 476–479, 2011. View at Google Scholar
  13. H.-F. Zhang, P. Hou, and W.-G. Xiao, “Clinical observation on effect of total glucosides of paeony in treating patients with non-systemic involved Sjogren syndrome,” Chinese Journal of Integrated Traditional and Western, vol. 27, no. 7, pp. 596–598, 2007. View at Google Scholar
  14. Y. Qin and Y.-P. Tian, “Protective effects of total glucosides of paeony and the underlying mechanisms in carbon tetrachloride-induced experimental liver injury,” Archives of Medical Science, vol. 7, no. 4, pp. 604–612, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. Chen, X.-P. Li, Z.-J. Li, L. Xu, and X.-M. Li, “Reduced hepatotoxicity by total glucosides of paeony in combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis,” International Immunopharmacology, vol. 15, no. 3, pp. 474–477, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Xiang, X.-M. Li, M.-J. Zhang et al., “Total glucosides of paeony can reduce the hepatotoxicity caused by Methotrexate and Leflunomide combination treatment of active rheumatoid arthritis,” International Immunopharmacology, vol. 28, no. 1, pp. 802–807, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. Y.-W. Wang and Y.-J. Wang, “Pharmacological study and clinical application of total glucosides of peony in autoimmune diseases,” Journal of Zhejiang University of Chinese Medicine, vol. 31, no. 2, pp. 240-241, 2007. View at Publisher · View at Google Scholar
  18. C. Vitali, S. Bombardieri, R. Jonsson et al., “Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European consensus group,” Annals of the Rheumatic Diseases, vol. 61, no. 6, pp. 554–558, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. “Cochrane Handbook for Systematic Reviews of Interventions Ver-sion 5. 1. 0,” March 2011, http://www.cochrane-handbook.org. View at Publisher · View at Google Scholar
  20. F.-H. Feng and E.-Z. Zhang, “42 cases of Sjögren's syndrom treated by total glucosides of peony,” Traditional Chinese Medicinal Research, vol. 21, no. 12, pp. 35–37, 2008. View at Google Scholar
  21. H. He, “Clinical investigation of Sjögren's syndrome treated with total glucosides of peony alliance with hydroxychloroquine,” Hubei Journal of Traditional Chinese Medicine, vol. 32, no. 11, pp. 30-31, 2008. View at Google Scholar
  22. W.-H. Cai, “Clinical investigation of Sjögren's syndrome treated with total glucosides of peony,” Contemporary Medicine, vol. 17, no. 36, pp. 10-11, 2011. View at Google Scholar
  23. B. Yin, “Clinical investigation of Sjögren's syndrome treated with total glucosides of peony alliance with hydroxychloroquine,” World Chinese Journal of Digestology, vol. 12, no. 35, pp. 20-21, 2011. View at Google Scholar
  24. X.-Y. Lin, R.-L. Chen, and L.-X. Zhu, “Clinical observation on effect of total glucosides of paeony in treatment of primary Sjögren's syndrome,” Journal of Aesthetics and Cosmetology, vol. 4, no. 24, 328 pages, 2011. View at Google Scholar
  25. H. Zhao and F.-T. Zhao, “Clinical study on treatment of primary Sjögren's syndrome by total glucosides of paeony and hydroxychloroquine,” Henan Traditional Chinese Medicine, vol. 33, no. 4, pp. 530-531, 2013. View at Google Scholar
  26. Y. Liu and H. Deng, “Clinical investigation of Sjögren's syndrome treated by total glucosides of peony alliance with methotrexate,” Chinese Journal of General Practice, vol. 14, no. 2, pp. 230–231+278, 2016. View at Google Scholar
  27. Y. Zhou, L. Jin, F. Kong et al., “Clinical and immunological consequences of total glucosides of paeony treatment in Sjögren's syndrome: a randomized controlled pilot trial,” International Immunopharmacology, vol. 39, pp. 314–319, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. M. I. Christodoulou, E. K. Kapsogeorgou, and H. M. Moutsopoulos, “Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome,” Journal of Autoimmunity, vol. 34, no. 4, pp. 400–407, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Nocturne and X. Mariette, “Advances in understanding the pathogenesis of primary Sjögren's syndrome,” Nature Reviews Rheumatology, vol. 9, no. 9, pp. 544–556, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Alunno, F. Carubbi, O. Bistoni et al., “CD4-CD8- T-cells in primary Sjögren's syndrome: association with the extent of glandular involvement,” Journal of Autoimmunity, vol. 51, pp. 38–43, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Jonsson, P. Vogelsang, R. Volchenkov, A. Espinosa, M. Wahren-Herlenius, and S. Appel, “The complexity of Sjögren's syndrome: Novel aspects on pathogenesis,” Immunology Letters, vol. 141, no. 1, pp. 1–9, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. M. J. Barrera, V. Bahamondes, D. Sepúlveda et al., “Sjögren's syndrome and the epithelial target: A comprehensive review,” Journal of Autoimmunity, vol. 42, pp. 7–18, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. O. J. Baker, J. M. Camden, R. S. Redman et al., “Proinflammatory cytokines tumor necrosis factor-α and interferon-γ alter tight junction structure and function in the rat parotid gland Par-C10 cell line,” American Journal of Physiology - Cell Physiology, vol. 295, no. 5, pp. C1191–C1201, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Alunno, O. Bistoni, E. Bartoloni et al., “IL-17-producing CD4-CD8- T cells are expanded in the peripheral blood, infiltrate salivary glands and are resistant to corticosteroids in patients with primary Sjögren's syndrome,” Annals of the Rheumatic Diseases, vol. 72, no. 2, pp. 286–292, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. W. H. Abdulahad, F. G. M. Kroese, A. Vissink, and H. Bootsma, “Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome,” Journal of Autoimmunity, vol. 39, no. 1-2, pp. 103–111, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Li, J. He, L. Zhu et al., “The clinical relevance of IL-17-producing CD4+CD161+ cell and its subpopulations in primary sjögren's syndrome,” Journal of Immunology Research, vol. 2015, Article ID 307453, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. G. Wu, N. Wu, T. Li, W. Lu, and G. Yu, “Total glucosides of peony ameliorates sjögren's syndrome by affecting TH1/TH2 cytokine balance,” Experimental and Therapeutic Medicine, vol. 11, no. 3, pp. 1135–1141, 2016. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Wang, J. Yuan, H.-X. Wu et al., “Total glucosides of paeony inhibit the inflammatory responses of mice with allergic contact dermatitis by restoring the balanced secretion of pro-/anti-inflammatory cytokines,” International Immunopharmacology, vol. 24, no. 2, pp. 325–334, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Zhang, R. Zhou, F. Zhou, H. Cheng, and B. Xia, “Total Glucosides of Peony Attenuates 2,4,6-Trinitrobenzene Sulfonic Acid/Ethanol-Induced Colitis in Rats Through Adjustment of Th1/Th2 Cytokines Polarization,” Cell Biochemistry and Biophysics, vol. 68, no. 1, pp. 83–95, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Lin, L. Xiao, G. Ouyang et al., “Total glucosides of paeony inhibits Th1/Th17 cells via decreasing dendritic cells activation in rheumatoid arthritis,” Cellular Immunology, vol. 280, no. 2, pp. 156–163, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. Z. Zhou, J. Lin, R. Huo et al., “Total glucosides of paeony attenuated functional maturation of dendritic cells via blocking TLR4/5 signaling in vivo,” International Immunopharmacology, vol. 14, no. 3, pp. 275–282, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. S. S. Song, P. F. Yuan, P. P. Li et al., “Protective Effects of Total Glucosides of Paeony on N-nitrosodiethylamine-induced Hepatocellular Carcinoma in Rats via Down-regulation of Regulatory B Cells,” Immunological Investigations, vol. 44, no. 6, pp. 521–535, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. N. Wang, Y. Zhang, Y. Wang et al., “The beneficial effect of total glucosides of paeony on psoriatic arthritis links to circulating tregs and th1 cell function,” Phytotherapy Research, vol. 28, no. 3, pp. 372–381, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. Wang, H. Zhang, G. Du et al., “Total glucosides of paeony (TGP) inhibits the production of inflammatory cytokines in oral lichen planus by suppressing the NF-κB signaling pathway,” International Immunopharmacology, vol. 36, pp. 67–72, 2016. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Su, P. Zhang, J.-J. Zhang, X.-M. Qi, Y.-G. Wu, and J.-J. Shen, “Effects of total glucosides of paeony on oxidative stress in the kidney from diabetic rats,” Phytomedicine, vol. 17, no. 3-4, pp. 254–260, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Feng and L. Ma, “Clinical efficacy of total glucosides of paeony in the treatment of primary Sjögren's syndrome,” West China Medical Journal, vol. 28, no. 09, pp. 1423–1425, 2013. View at Google Scholar
  47. J. Lu, H. Shen, and Y. Liu, “Clinical observation of total glucosides of paeony on Sjögren's syndrome,” China Journal of Modern Medicine, vol. 16, no. 1, pp. 78–80, 2006. View at Google Scholar
  48. H. Wang, “Clinical observation of total glucosides of paeony on Sjögren's syndrome,” Gan Su Journal of Traditional Chinese Medicine, vol. 21, no. 5, pp. 54-55, 2008. View at Google Scholar